Search

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Highlights from the SWG

Impactful activitiesGuideline development projectThe most relevant and impactful activities of the SWG include those related to the guideline development project. There were regular meetings with the Guidelines Expert Panel Committee.

Publications

The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review
Salek, S. ; Ionova, T. ; Oliva, E. N. ; Andreas, M. ; Skoetz, N. ; Kreuzberger, N. ; Laane, E.

Highlights from the SWG

SWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

SWG Educational Activities

EventsSWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

SWG Educational Activities

EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten

Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Highlights from the SWG

Standards for functional precision medicine projectStandards for functional precision medicine, a project initiated by EHA's SWG on Precision Hematology, received a 2023 SWG Grant and is currently underway.

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.